Pleuromutilin-22-mesylate

Pleuromutilin-22-mesylate is a semi-synthetic antibiotic derived from the fungus Pleurotus mutilus. It is used in the treatment of bacterial infections caused by Gram-positive bacteria, including Streptococcus pneumoniae, Staphylococcus aureus, and Clostridium perfringens. Pleuromutilin-22-mesylate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, which prevents the elongation of peptidyl-tRNA and the formation of peptide bonds. This leads to the inhibition of bacterial growth and ultimately, bacterial death. Pleuromutilin-22-mesylate is administered orally and has excellent bioavailability. It is rapidly absorbed and distributed throughout the body, including into the lungs, where it is effective against respiratory tract infections. The drug is primarily metabolized in the liver and excreted in the urine and feces. Pleuromutilin-22-mesylate is a potent antibacterial agent with a low risk of developing resistance. It has a broad spectrum of activity against Gram-positive bacteria and is effective against strains that are resistant to other antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA). The drug has a good safety profile and is generally well-tolerated by patients. However, like all antibiotics, it can cause side effects, including gastrointestinal disturbances, allergic reactions, and liver toxicity. Overall, Pleuromutilin-22-mesylate is an important tool in the fight against bacterial infections, especially those caused by Gram-positive bacteria. Its unique mechanism of action and low risk of resistance make it a valuable addition to the antibiotic arsenal.